DICE Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DICE Therapeutics, Inc. - overview
Established
2013
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2013 by founder and CEO Kevin Judice and Phil Patten, DICE Therapeutics, Inc. operates as a developer of a transformative platform to discover novel small molecules. As of August 2021, the company had raised a total of USD 187. 4 million in financing.
The company raised USD 204 million in an initial public offering (IPO) on the Nasdaq under the ticker code DICE in September 2021. DICE Therapeutics, Inc. operates as a biotechnology company that develops small molecule compounds for targeted oral medicines through protein-protein interaction (PPI) therapeutics to treat patients with serious medical conditions. The funds collected from the IPO in September 2021, will be used to promote the development of oral medicines that might compete with biological treatments.
Current Investors
Agent Capital, Northpond Ventures, Alexandria Venture Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.dicetherapeutics.com/
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.